Clinical trials
Melanoma clinical trials
A serious form of skin cancer that develops in pigment-producing cells. We’re tracking 458 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06594991RecruitingPhase 2
A study of three immunotherapy drugs for advanced melanoma
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06581406RecruitingPhase 2/Phase 3
RP2 with nivolumab for untreated uveal melanoma
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges Any age - NCT06550674Recruiting
Genetic study for uveal melanoma risk
This study looks for new inherited genes linked to uveal melanoma (an eye cancer). If you have this cancer and don't already have a known genetic cause, you may be able to help find new genes that affect cancer risk.
Clermont-Ferrand, Puy-de-DômeAges 18 years+ - NCT04424719Recruiting
Follow-up study for high-risk eye melanoma after treatment
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
ParisAges 18 years+ - NCT06545682RecruitingPhase 1
Study of alpelisib and pembrolizumab for advanced breast cancer or melanoma
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
Houston, TexasAges 18 years+ - NCT06536257Recruiting
Personalized immunotherapy prediction for melanoma and other cancers
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Sydney, New South WalesAges 18 years+ - NCT06548789RecruitingPhase 2
Diet and immunotherapy before surgery for melanoma
This study tests whether adding a special diet (with prebiotic foods) to standard immunotherapy before surgery helps your body fight melanoma better. It may improve how well the treatment works and reduce side effects.
Houston, TexasAges 18 years+ - NCT06508775Recruiting
Long-term checkup for Miltenyi cell therapy patients
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
BerlinAges Any age - NCT06488482RecruitingPhase 3
Short immunotherapy after melanoma surgery
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
HelsinkiAges 18 years+ - NCT06472661RecruitingEarly Phase 1
Focused ultrasound plus drug injection for melanoma before surgery
This trial tests a new combination approach for advanced melanoma that is planned for surgical removal. It uses focused ultrasound to heat the tumor, followed by an injection of an experimental immune-stimulating drug (polyICLC), while you continue your standard immunotherapy. The goal is to make the immune system attack the cancer more effectively.
Charlottesville, VirginiaAges 18 years+ - NCT06466434Recruiting
Prebiotic diet to boost immunotherapy for melanoma
This trial tests whether a special prebiotic diet can help your body's bacteria (microbiome) better respond to standard immunotherapy for advanced melanoma that cannot be removed by surgery. If you are starting your first immunotherapy, you may be able to join.
Houston, TexasAges 18 years+ - NCT06414590RecruitingPhase 2
Tebentafusp before surgery for eye melanoma
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06400550Recruiting
Melanoma metabolism and spread risk study
This study looks at how the body's metabolism might affect the spread of melanoma. Researchers want to see if certain metabolic traits in people with melanoma are linked to a higher risk of the cancer spreading.
Dallas, TexasAges 18 years+ - NCT06388252Enrolling by invitation
ECT changes in melanoma skin tumors
This study tests how electrochemotherapy (ECT) changes the area around melanoma tumors in the skin. It may help doctors understand why ECT works and who benefits most.
LjubljanaAges 18–100 - NCT01205815Recruiting
Use and storage of leftover melanoma tissue for future testing
This study collects and stores leftover melanoma tissue (and sometimes blood) for future research and testing. If the trial uses your stored samples to help match treatments, it could support better care planning over time.
Nashville, TennesseeAges 18 years+ - NCT06365619RecruitingPhase 2
Immunotherapy before surgery for recurrent melanoma
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
Salt Lake City, UtahAges 18 years+ - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Gilbert, ArizonaAges 12 years+ - NCT06246149RecruitingPhase 3
Tebentafusp after treatment for high-risk eye melanoma
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Lake Success, New YorkAges 18 years+ - NCT06246916RecruitingPhase 3
Testing a new immunotherapy combo for advanced melanoma
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Chandler, ArizonaAges 18 years+ - NCT06216938RecruitingEarly Phase 1
RP1 virus therapy for advanced melanoma to lower lymph node spread risk
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06214156RecruitingPhase 1/Phase 2
T3011 for advanced melanoma
This trial tests a new treatment, T3011, which is a virus that targets and kills cancer cells while also boosting your immune system. It's for people with advanced melanoma, and the goal is to see if it can shrink tumors and help you live longer.
BeijingAges 18 years+ - NCT06194929RecruitingPhase 1/Phase 2
Drug combo for melanoma that spread to the brain
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
Iowa City, IowaAges 18 years+ - NCT06112314RecruitingPhase 3
New immunotherapy combo for advanced melanoma (first treatment)
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
Tucson, ArizonaAges 18 years+ - NCT06121180RecruitingPhase 2
Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for melanoma?
- Yes. Clin2 currently lists 458 recruiting melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.